Trinidad’s Ministry of Health, through its Chemistry, Food, and Drugs Division, has advised of a voluntary recall notice for Zenzedi CII (dextroamphetamine sulfate tablets, USP) 30 mg, prompted by Azurity Pharmaceuticals, Inc.
The recall is attributed to the presence of Carbinoxamine Maleate, a substance found in the packaging.
Risks to patient safety
Zenzedi, typically prescribed for Narcolepsy and ADHD, poses potential hazards due to the inclusion of Carbinoxamine Maleate.
This compound can induce drowsiness, central nervous system depression, elevated eye pressure, prostate enlargement, urinary obstruction, and thyroid disorders.
Patients reliant on Zenzedi face heightened risks of accidents or injuries due to its sedative effects.
Recommended actions
While Zenzedi is not officially registered for sale in the country, the Ministry urges immediate cessation of its use and advises consumers to return the medication to the point of purchase as a precautionary measure.
The Ministry said it will continue to monitor the situation and will advise the public as necessary.
